Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events

References

• DiazLMarabelleADelordJ-PPembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC [abstract and poster at ASCO 2017 Annual Meeting]J Clin Oncol201735Suppl abstr3071
   Google Scholar
• RibasAPuzanovIDummerRPembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialLancet Oncol201516890891826115796
   PubMed Web of Science ®Google Scholar
• SeiwertTYBurtnessBMehraRSafety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trialLancet Oncol201617795696527247226
   PubMed Web of Science ®Google Scholar
• LarkinJChiarion-SileniVGonzalezRCombined nivolumab and ipilimumab or monotherapy in untreated melanomaN Engl J Med20153731233426027431
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBMcDermottDFNivolumab versus everolimus in advanced renal-cell carcinomaN Engl J Med2015373191803181326406148
   PubMed Web of Science ®Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med2015373212313526028407
   PubMed Web of Science ®Google Scholar
• RosenbergJEHoffman-CensitsJPowlesTAtezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialLancet2016387100311909192026952546
   PubMed Web of Science ®Google Scholar
• MassardCGordonMSSharmaSSafety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancerJ Clin Oncol201634263119312527269937
   PubMed Web of Science ®Google Scholar
• HodiFSChesneyJPavlickACCombined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trialLancet Oncol201617111558156827622997
   PubMed Web of Science ®Google Scholar
• KaufmanHLRussellJHamidOAvelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trialLancet Oncol201617101374138527592805
   PubMed Web of Science ®Google Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456
   PubMed Web of Science ®Google Scholar
• FerrisRLBlumenscheinGJrFayetteJNivolumab for recurrent squamous-cell carcinoma of the head and neckN Engl J Med2016375191856186727718784
   PubMed Web of Science ®Google Scholar
• RittmeyerABarlesiFWaterkampDAtezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialLancet20173891006625526527979383
   PubMed Web of Science ®Google Scholar
• YounesASantoroAShippMNivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trialLancet Oncol20161791283129427451390
   PubMed Web of Science ®Google Scholar
• SharmaPRetzMSiefker-RadtkeANivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialLancet Oncol201718331232228131785
   PubMed Web of Science ®Google Scholar
• ReckMRodriguez-AbreuDRobinsonAGPembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancerN Engl J Med2016375191823183327718847
   PubMed Web of Science ®Google Scholar
• BalarAVGalskyMDRosenbergJEIMvigor210 Study GroupAtezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialLancet201738910064677627939400
   PubMed Web of Science ®Google Scholar
• BalarACastellanoDO’DonnellPPembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: results from the total KEYNOTE-052 study population [abstract and poster presented at ASCO 2017 Genitourinary Cancers Symposium]J Clin Oncol201735Suppl 6S abstr284
   Google Scholar
• ApoloABInfanteJRBalmanoukianAAvelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, Phase Ib StudyJ Clin Oncol201735192117212428375787
   PubMed Web of Science ®Google Scholar
• BellmuntJde WitRVaughnDJKEYNOTE-045 InvestigatorsPembrolizumab as second-line therapy for advanced urothelial carcinomaN Engl J Med2017376111015102628212060
   PubMed Web of Science ®Google Scholar
• LangerCJGadgeelSMBorghaeiHKEYNOTE-021 investigatorsCarboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 studyLancet Oncol201617111497150827745820
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Company Yervoy^® (ipilimumab) injection [prescribing information]Princeton, NJBristol-Myers Squibb Company2017
   Google Scholar
• Bristol-Myers Squibb Company Opdivo^® (nivolumab) injection [prescribing information]Princeton, NJBristol-Myers Squibb Company2017
   Google Scholar
• Merck & Company IncKeytruda^® (pembrolizumab) for injection [prescribing information]Whitehouse Station, NJMerck & Co Inc2017
   Google Scholar
• Genentech IncTecentriq^® (atezolizumab) injection [prescribing information]South San Francisco, CAGenentech, Inc2017
   Google Scholar
• EMD Serono IncBavencio^® (avelumab) injection, for intravenous use [prescribing information]Rockland, MDEMD Serono, Inc. and Pfizer, Inc2017
   Google Scholar
• AstraZeneca Pharmaceuticals LPImfinzi™ (durvalumab) injection, for intravenous use [prescribing information]Wilmington, DEAstraZeneca Pharmaceuticals LP2017
   Google Scholar
• NandaRChowLQDeesECPembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 studyJ Clin Oncol201634212460246727138582
   PubMed Web of Science ®Google Scholar
• MuroKChungHCShankaranVPembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trialLancet Oncol201617671772627157491
   PubMed Web of Science ®Google Scholar
• ReardonDASampsonJHSahebjamSSafety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): updated results from checkmate-143 [abstract and poster presented at ASCO 2016 Annual Meeting]J Clin Oncol20163415 Suppl abstr2014
   Web of Science ®Google Scholar
• AntoniaSJLopez-MartinJABendellJNivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trialLancet Oncol201617788389527269741
   PubMed Web of Science ®Google Scholar
• HamanishiJMandaiMIkedaTSafety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancerJ Clin Oncol201533344015402226351349
   PubMed Web of Science ®Google Scholar
• MeleroISangroBYauTNivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): the CheckMate 040 study [abstract, poster, and slides presented at ASCO 2017 Gastrointestinal Cancers Symposium]J Clin Oncol201735Suppl 4s abstr226
   Google Scholar
• PfizerAvelumab in previously untreated patients with epithelial ovarian cancer (JAVELIN OVARIAN 100)2016 Available from: https://clinicaltrials.gov/ct2/show/NCT02718417. NLM identifier: NCT02718417Accessed April 10, 2017
   Google Scholar
• RibasAHansonDCNoeDATremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancerOncologist200712787388317673618
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkSmall Cell Lung Cancer (v3.2017)2017 Available from: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdfAccessed March 15, 2017
   Google Scholar
• PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer201212425226422437870
   PubMed Web of Science ®Google Scholar
• McDermottDFAtkinsMBPD-1 as a potential target in cancer therapyCancer Med20132566267324403232
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• EggermontAMChiarion-SileniVGrobJJAdjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trialLancet Oncol201516552253025840693
   PubMed Web of Science ®Google Scholar
• RobertCLongGVBradyBNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med2015372432033025399552
   PubMed Web of Science ®Google Scholar
• RobertCSchachterJLongGVKEYNOTE-006 InvestigatorsPembrolizumab versus ipilimumab in advanced melanomaN Engl J Med2015372262521253225891173
   PubMed Web of Science ®Google Scholar
• HerbstRSBaasPKimDWPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet2016387100271540155026712084
   PubMed Web of Science ®Google Scholar
• FehrenbacherLSpiraABallingerMKEYNOTE-006 InvestigatorsAtezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLancet2016387100301837184626970723
   PubMed Web of Science ®Google Scholar
• MoskowitzCZinzaniPFanaleMPembrolizumab in relapsed/refractory classical Hodgkin lymphoma: primary end point analysis of the Phase 2 Keynote-087 Study [presented at ASH 58th Annual Meeting, Dec 3–6; San Diego, CA]Blood201612822 abstr1107
   Web of Science ®Google Scholar
• LeDTUramJNWangHPD-1 blockade in tumors with mismatch-repair deficiencyN Engl J Med2015372262509252026028255
   PubMed Web of Science ®Google Scholar
• PostowMACallahanMKWolchokJDImmune checkpoint blockade in cancer therapyJ Clin Oncol201533171974198225605845
   PubMed Web of Science ®Google Scholar
• KumarVChaudharyNGargMFloudasCSSoniPChandraABCurrent diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapyFront Pharmacol201784928228726
   PubMed Web of Science ®Google Scholar
• Abdel-WahabNShahMSuarez-AlmazorMEAdverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reportsPLoS One2016117e016022127472273
   PubMed Web of Science ®Google Scholar
• GaronEBRizviNAHuiRKEYNOTE-001 InvestigatorsPembrolizumab for the treatment of non-small-cell lung cancerN Engl J Med2015372212018202825891174
   PubMed Web of Science ®Google Scholar
• RobertCRibasAWolchokJDAnti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialLancet201438499481109111725034862
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [webpage on the Internet]Modification of the Dosing Regimen for Nivolumab2016 Available from: www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm520871.htmAccessed March 24, 2017
   Google Scholar
• HellmannMDRizviNAGoldmanJWNivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort studyLancet Oncol2017181314127932067
   PubMed Web of Science ®Google Scholar
• LongGAtkinsonVCebonJPembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: results of the KEYNOTE-029 expansion cohort [abstract and slide presentation at ASCO 2016]J Clin Oncol201634Suppl abstr9506
   Google Scholar
• RizviNBarlesiFBrahmerJPhase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTICJ Immunother Cancer20153Suppl 2P171
   Google Scholar
• WeberJSKahlerKCHauschildAManagement of immune-related adverse events and kinetics of response with ipilimumabJ Clin Oncol201230212691269722614989
   PubMed Web of Science ®Google Scholar
• WeberJSPostowMLaoCDSchadendorfDManagement of adverse events following treatment with anti-programmed death-1 agentsOncologist201621101230124027401894
   PubMed Web of Science ®Google Scholar
• PowlesTO’DonnellPHMassardCUpdated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma [abstract and poster presented at ASCO 2017 Genitourinary Cancers Symposium]J Clin Oncol2017356 Suppl abstr286
   Web of Science ®Google Scholar
• PatelMEllertonJInfanteJAgrawalMAvelumab in patients with metastatic urothelial carcinoma: pooled results from two cohorts of the phase 1b JAVELIN Solid Tumor trial [abstract and poster presented at ASCO 2017 Genitourinary Cancers Symposium]J Clin Oncol2017Suppl 6 abstr330
   Google Scholar
• ApoloAEllertonJInfanteJUpdated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study [abstract and slide presentation at ASCO 2017 Annual Meeting]J Clin Oncol201735Suppl abstr4528
   Google Scholar
• WeberJSD’AngeloSPMinorDNivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialLancet Oncol201516437538425795410
   PubMed Web of Science ®Google Scholar
• BelumVRBenhuriBPostowMACharacterisation and management of dermatologic adverse events to agents targeting the PD-1 receptorEur J Cancer201660122527043866
   PubMed Web of Science ®Google Scholar
• ThebeauMRubinKHofmannMGrimmJWeinsteinAChoiJNManagement of skin adverse events associated with immune checkpoint inhibitors in patients with melanoma: a nursing perspectiveJ Am Assoc Nurse Pract201729529430328436601
   PubMed Web of Science ®Google Scholar
• WeberJSHodiFSWolchokJDSafety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanomaJ Clin Oncol201735778579228068177
   PubMed Web of Science ®Google Scholar
• DayDKhojaLChenTW-WSiuLLHansenARTumor- and class-specific patterns of immune-related adverse events (irAEs) of immune checkpoint inhibitors (ICIs): a systematic review (SR) [abstract and poster presented at 2016 ASCO Annual Meeting]J Clin Oncol20163415 Suppl abstr3065
   Web of Science ®Google Scholar
• GoldingerSMStiegerPMeierBCytotoxic cutaneous adverse drug reactions during anti-PD-1 therapyClin Cancer Res201622164023402926957557
   PubMed Web of Science ®Google Scholar
• PostowMA webpage on the InternetASCO Educational Book: Managing Immune Checkpoint-Blocking Antibody Side Effects2015 Available from: http://meetinglibrary.asco.org/content/115000076-156Accessed April 10, 2017
   Google Scholar
• VilladolidJAminAImmune checkpoint inhibitors in clinical practice: update on management of immune-related toxicitiesTransl Lung Cancer Res20154556057526629425
   PubMed Web of Science ®Google Scholar
• ByunDJWolchokJDRosenbergLMGirotraMCancer immunotherapy – immune checkpoint blockade and associated endocrinopathiesNat Rev Endocrinol201713419520728106152
   PubMed Web of Science ®Google Scholar
• MichotJMBigenwaldCChampiatSImmune-related adverse events with immune checkpoint blockade: a comprehensive reviewEur J Cancer20165413914826765102
   PubMed Web of Science ®Google Scholar
• ReubenAHy’s lawHepatology200439257457814768020
   PubMed Web of Science ®Google Scholar
• BjornssonEDrug-induced liver injury: Hy’s rule revisitedClin Pharmacol Ther200679652152816765139
   PubMed Web of Science ®Google Scholar
• WanchooRKaramSUppalNNCancer and Kidney International Network Workgroup on Immune Checkpoint InhibitorsAdverse renal effects of immune checkpoint inhibitors: a narrative reviewAm J Nephrol201745216016928076863
   PubMed Web of Science ®Google Scholar
• DillardTYedinakCGAlumkalJFleseriuMAnti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypesPituitary2010131293819639414
   PubMed Web of Science ®Google Scholar
• CalabreseCKirchnerEKontziasKVelchetiVCalabreseLHRheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entityRMD Open201731e00041228405474
   PubMed Web of Science ®Google Scholar
• CappelliLCGutierrezAKBaerANInflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumabAnn Rheum Dis2017761435027307501
   PubMed Web of Science ®Google Scholar
• CappelliLCNaidooJBinghamCO3rdShahAAInflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatmentImmunotherapy2017915828000525
   PubMed Web of Science ®Google Scholar
• SpainLWallsGJulveMNeurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literatureAnn Oncol201728237738528426103
   PubMed Web of Science ®Google Scholar
• YunSVinceletteNDMansourIHaririDMotamedSLate onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complicationCase Rep Oncol Med2015201579484225918658
   PubMedGoogle Scholar
• HeinzerlingLOttPAHodiFSCardiotoxicity associated with CTLA4 and PD1 blocking immunotherapyJ Immunother Cancer201645027532025
   PubMed Web of Science ®Google Scholar
• AhmadSLewisMCorriePIddawelaMIpilimumab-induced thrombocytopenia in a patient with metastatic melanomaJ Oncol Pharm Pract201218228729221807763
   PubMedGoogle Scholar
• PallaARKennedyDMosharrafHDollDAutoimmune hemolytic anemia as a complication of nivolumab therapyCase Rep Oncol20169369169727920704
   PubMed Web of Science ®Google Scholar
• NairRGheithSNairSGImmunotherapy-associated hemolytic anemia with pure red-cell aplasiaN Engl J Med2016374111096109726981948
   PubMed Web of Science ®Google Scholar
• ShiuanEBeckermannKEOzgunAThrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapyJ Immunother Cancer20175828239462
   PubMed Web of Science ®Google Scholar
• WeberJS webpage on the InternetThe Clinicians’ Guide to Managing Immune-Related Adverse Events: An Interactive Algorithm Tool2016 Available from: http://www.clinicaloptions.com/Oncology/Treatment%20Updates/Immune%20Related%20AEs/Algorithm%20Tool/Interactive_Algorithm_Tool.aspxAccessed December 1, 2016
   Google Scholar
• LedezmaBHengAReal-world impact of education: treating patients with ipilimumab in a community practice settingCancer Manag Res20146514
   Web of Science ®Google Scholar
• National Cancer InstituteCommon Terminology Criteria for Adverse Events (v4.0)2010 Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdfAccessed March 15, 2017
   Google Scholar
• JohnsonDBSullivanRJOttPAIpilimumab therapy in patients with advanced melanoma and preexisting autoimmune disordersJAMA Oncol20162223424026633184
   PubMed Web of Science ®Google Scholar
• MenziesAMJohnsonDBRamanujamSAnti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabAnn Oncol201728236837627687304
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationYervoy™ (ipilimumab) Risk Evaluation and Mitigation Strategy (REMS)2012 Available from: http://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm249435.pdfAccessed October 1, 2016
   Google Scholar
• FecherLAAgarwalaSSHodiFSWeberJSIpilimumab and its toxicities: a multidisciplinary approachOncologist201318673374323774827
   PubMed Web of Science ®Google Scholar
• Merck & Company IncA Guide to Monitoring Patients during Treatment with Keytruda2017 Available from: https://www.keytruda.com/static/pdf/adverse-reaction-management-tool.pdfAccessed March 29, 2017
   Google Scholar
• Bristol-Myers SquibbYervoy Immune-Mediated Adverse Reactions Management Guide2015 Available from: http://www.hcp.yervoy.com/servlet/servlet.FileDownload?file=00Pi000000TUzayEADAccessed March 24, 2017
   Google Scholar
• Bristol-Myers SquibbOpdivo Immune-Mediated Adverse Reactions Management Guide2017 Available from: http://www.opdivohcp.com/servlet/servlet.FileDownload?file=00Pi000000kLoKcEAKAccessed March 24, 2017
   Google Scholar
• Genentech IncManaging Select Tecentriq Immune-Related Adverse Events2016 Available from: www.tecentriq.com/content/dam/gene/tecentriq/Tecentriq-Adverse-Event-Management-Brochure.pdfAccessed December 8, 2016
   Google Scholar
• AstraZeneca Pharmaceuticals LPImfinzi Adverse Events Management Handbook2017 Available from: https://www.imfinzi.com/content/dam/website-services/us/434-imfinzi-com/hcp/pdf/imAE_management_handbook.pdfAccessed July 13, 2017
   Google Scholar
• HorvatTZAdelNGDangTOImmune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial Sloan Kettering Cancer CenterJ Clin Oncol201533283193319826282644
   PubMed Web of Science ®Google Scholar
• Merck & Company IncA Nurse’s Guide to Keytruda2016 Available from: https://www.keytruda.com/static/pdf/nurse-guide-to-treatment-monitoring.pdfAccessed March 17, 2017
   Google Scholar
• Bristol-Myers Squibb [webpage on the Internet]The Opdivo Safety Tool2016 Available from: https://www.opdivosafetytool.com/#/superhomeAccessed March 17, 2017
   Google Scholar
• LukeJJOttPAPD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanomaOncotarget2015663479349225682878
   PubMedGoogle Scholar
• BriotKCortetBRouxCBone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO)2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosisJoint Bone Spine201481649350125455041
   PubMed Web of Science ®Google Scholar
• FDA approves Merck’s Keytruda® (pembrolizumab) for adult and pediatric patients with classical Hodgkin lymphoma (cHL) refractory to treatment, or who have relapsed after three or more prior lines of therapy [press release]; 2017.
   Google Scholar
• US FDA accepts first biologics license application for AstraZeneca’s durvalumab in bladder cancer [press release]; 2016.
   Google Scholar
• PostowMAChesneyJPavlickACNivolumab and ipilimumab versus ipilimumab in untreated melanomaN Engl J Med2015372212006201725891304
   PubMed Web of Science ®Google Scholar
• AstraZeneca Pharmaceuticals LP [homepage on the Internet]Lighthouse Program2017 Available from: https://www.lighthouseprogram.com/Accessed May 3, 2017
   Google Scholar